Diazepane Derivatives, Processes for their Preparation, and Uses thereof for the Amelioration, Prevention and/or Treatment of Mental and Neurological Diseases
US-2024246957-A1 · Jul 25, 2024 · US
US10858370B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10858370-B2 |
| Application number | US-201816637484-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 8, 2018 |
| Priority date | Nov 1, 2017 |
| Publication date | Dec 8, 2020 |
| Grant date | Dec 8, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described herein is a process for preparing a compound of formula (I) starting from a compound of formula (II), where the process is catalyzed by a Ruthenium complex.
Opening claim text (preview).
The invention claimed is: 1. A process for the preparation of a compound of formula (I) in a form of any one of its stereoisomers or a mixture thereof and wherein R 1 represents a linear or branched C 1-5 alkanediyl or alkenediyl group, optionally substituted by a phenyl group and R 2 represents a linear or branched C 1-10 alkanediyl or alkenediyl group, optionally substituted by a phenyl group, the process comprising reacting a compound of formula (II) in a form of any one of its stereoisomers and wherein R 1 and R 2 have the same meaning as defined in formula (I) with a ruthenium catalyst and in the presence of a base and a hydrogen source. 2. The process according to claim 1 , characterized in that R 1 represents a linear or branched C 1-4 alkanediyl group. 3. The process according to claim 1 , characterized in that R 1 represents a linear or branched C 2-3 alkanediyl group. 4. The process according to according to claim 1 , characterized in that R 1 represents a 1,2-propanediyl group or 1,2-ethanediyl group. 5. The process according to claim 1 characterized in that R 2 represents a linear or branched C 4-9 alkanediyl group. 6. The process according to claim 1 , characterized in that R 2 represents a linear or branched C 6-9 alkanediyl group. 7. The process according to claim 1 , characterized in that R 2 represents a 1,8-octanediyl group. 8. The process according to claim 1 , characterized in that compound of formula (I) is selected from the group consisting of 12-oxabicyclo[6.3.1]dodec-8-ene, 10-methyl-12-oxabicyclo[6.3.1]dodec-8-ene, 13-oxabicyclo[7.3.1]tridec-9-ene, 11-methyl-13-oxabicyclo[7.3.1]tridec-9-ene, 14-oxabicyclo[8.3.1]tetradec-10-ene, 12-methyl-14-oxabicyclo[8.3.1]tetradec-10-ene, 15-oxabicyclo[9.3.1]pentadec-11-ene, 13-methyl-15-oxabicyclo[9.3.1]pentadec-11-ene, 16-oxabicyclo[10.3.1]hexadec-12-ene, 14-methyl-16-oxabicyclo[10.3.1]hexadec-12-ene, 17-oxabicyclo[11.3.1]heptadec-13-ene, and 15-methyl-17-oxabicyclo[11.3.1]heptadec-13-ene. 9. The process according to claim 1 , characterized in that compound of formula (II) is selected from the group consisting of cycloundecane-1,5-dione, 3-methylcycloundecane-1,5-dione, cyclododecane-1,5-dione, 3-methycyclododecane-1,5-dione, cyclotridecane-1,5-dione, 3-methycyclotridecane-1,5-dione, cyclotetradecane-1,5-dione, 3-methycyclotetradecane-1,5-dione, cyclopentadecane-1,5-dione, 3-methycyclopentadecane-1,5-dione, cyclohexadecane-1,5-dione, and 3-methycyclohexadecane-1,5-dione. 10. The process according to claim 1 , characterized in that the ruthenium catalyst is of formula [Ru(X) 2 P n ] (III) wherein X represents an anionic ligand; and when n is an integer between 1 to 4, P represents a monophosphine monodendate ligand or when n is an integer between 1 to 2, P represents a biphosphine bidentate ligand. 11. The process according to claim 1 , characterized in that the ruthenium catalyst is selected from the group consisting of [Ru(H)(Cl)(PPh 3 ) 3 ], [Ru(H) 2 (PPh 3 ) 3 ], [Ru(OAc) 2 (PPh 3 ) 2 ], [Ru(OPiv) 2 (PPh 3 ) 2 ], [Ru(Cl) 2 (PBu 3 ) 3 ], and [Ru(Cl) 2 (PPh 3 ) 3 ]. 12. The process according to claim 1 , characterized in that the base is selected from the group consisting of pyridine, trimethylamine, lutidine, N,N-Diisopropylethylamine, 1,8-Diazabicyclo[5.4.0]undec-7-ene, alkali metal alkoxide, carboxylate, carbonate, or hydroxide, and a mixture thereof. 13. The process according to claim 1 , characterized in that the hydrogen source is a hydrocarbon comprising at least one secondary alcohol functional group and having a boiling point equal to or above 110° C. 14. The process according to claim 1 , characterized in that the hydrogen source is of formula wherein R 3 and R 4 , independently from each other, represent a C 1-10 linear alkyl group optionally substituted by a hydroxy group or an aryl group, a C 2-10 linear alkenyl group optionally substituted by a hydroxy group or an aryl group, a C 3-10 branched or cyclic alkyl or alkenyl group optionally substituted by a hydroxy group or an aryl group, or a phenyl group optionally substituted by one to five C 1-3 alkyl or alkoxy groups, hydroxy groups or halogen atoms; or R 3 and R 4 , when taken together, represent a C 2-10 linear or branched alkanediyl or alkenediyl optionally substituted by a hydroxy group or an aryl group. 15. The process according to claim 1 , characterized in that the hydrogen source is 1-phenylethan-1-ol, 2-methyl-2,4-pentanediol, cyclohexanol, 4-methylpentan-2-ol, cyclopentanol, or octan-2-ol.
Bridged systems · CPC title
Phosphines {, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.